AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Single Dose PD & PK Study With Two Formulations of Abediterol in Patients With Asthma
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT02777827
- Locations
- 🇩🇪
Research Site, Wiesbaden, Germany
PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 169
- Registration Number
- NCT02777658
- Locations
- 🇩🇪
Research Site, Zittau, Germany
KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)
Completed
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 315
- Registration Number
- NCT02777567
- Locations
- 🇰🇷
Research Site, South Korea, Korea, Republic of
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: AZD9567 80 mgDrug: AZD9567 155 mgDrug: AZD9567 40 mgDrug: AZD9567 20 mgDrug: AZD9567 125 mgDrug: AZD9567 10 mg
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT02760316
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Observational Study of Obstructive Lung Disease (NOVELTY)
Completed
- Conditions
- Chronic Obstructive Pulmonary DiseaseCOPDAsthma
- Interventions
- Procedure: Blood drawProcedure: UrineProcedure: Lung function measurementsProcedure: Fractional Exhaled Nitric Oxide (FENO)
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12255
- Registration Number
- NCT02760329
- Locations
- 🇬🇧
Research Site, York, United Kingdom
Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)
Completed
- Conditions
- All Patients Treated With the Product
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3494
- Registration Number
- NCT02756039
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus
Terminated
- Conditions
- Type II Diabetes Mellitus
- Interventions
- Other: Use of digital disease management tool in participants with T2DM
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 57
- Registration Number
- NCT02749435
- Locations
- 🇬🇧
Research Site, Stockport, United Kingdom
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
Phase 1
Completed
- Conditions
- Advanced Solid MalignanciesNon-Small Cell Lung Cancer (NSCLC)Colorectal Carcinoma (CRC)Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)
- Interventions
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 313
- Registration Number
- NCT02740985
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
Phase 1
Active, not recruiting
- Conditions
- BreastSCLCGastric CancersOvarian
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 264
- Registration Number
- NCT02734004
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in Algeria
Completed
- Conditions
- EpidemiologyOncologyBreast Cancer
- Interventions
- Other: NIS (Non Interventional Study) observational study
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT02733601
- Locations
- 🇩🇿
Research Site, Ouest Of Algeria/ Oran Region, Algeria